A metalloproteinase inhibitor prevents acute graft-versus-host disease in mice after bone marrow transplantation

[1]  J. Crawford,et al.  Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. , 1997, Blood.

[2]  K. Yoshino,et al.  A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. , 1997, Blood.

[3]  Y. Obata,et al.  Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors. , 1997, Bioorganic & medicinal chemistry.

[4]  T. Macdonald,et al.  A major role for matrix metalloproteinases in T cell injury in the gut. , 1997, Journal of immunology.

[5]  E. Podack,et al.  The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice , 1996, The Journal of experimental medicine.

[6]  J. Tschopp,et al.  Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease , 1996, The Journal of experimental medicine.

[7]  K. Yoshino,et al.  Metalloproteinase-mediated Release of Human Fas Ligand , 1995 .

[8]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[9]  E. Smeland,et al.  Role of the 75-kDa tumor necrosis factor receptor: inhibition of early hematopoiesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Gerhart,et al.  Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing , 1994, Nature.

[11]  Terry Farrah,et al.  The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.

[12]  P. Tiberghien,et al.  Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. , 1992, Blood.

[13]  P. Vassalli,et al.  Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease , 1987, The Journal of experimental medicine.

[14]  D. Williams,et al.  The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. , 1986, Journal of immunology.

[15]  S. Pals,et al.  Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. , 1984, Immunology today.

[16]  K. Oshimi,et al.  Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. , 1998, Blood.

[17]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[18]  A. H. Drummond,et al.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases. , 1994, Nature.

[19]  R. Bast,et al.  Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. , 1994, Nature.

[20]  K. Koretz,et al.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[21]  R. Storb,et al.  Human marrow transplantation: an immunological perspective. , 1987, Advances in immunology.

[22]  Graft-versus-host disease after marrow transplantation. , 1984, Lancet.